The Trump administration has reclassified FDA‑approved, state‑licensed marijuana from Schedule I to Schedule III, Acting Attorney General Todd Blanche announced Thursday. The move expands medical research opportunities and patient access, though it does not yet apply to marijuana generally.
Trump Signs Executive Order on Psychedelic Research
Blanche said the order initiates an expedited hearing to fully reschedule the drug. Days earlier, President Donald Trump signed an executive order accelerating review of psychedelic therapies, citing their potential to help veterans with PTSD and depression.
He highlighted Stanford research showing ibogaine treatment reduced symptoms by up to 90 percent in special operations veterans. The administration says reforms will clear bureaucratic hurdles, improve FDA‑VA data sharing, and fast‑track rescheduling of approved psychedelic drugs, marking a significant shift in U.S. drug policy.
Follow us on:
Read More News at #latestmalaysia #BusinessNews and #WorldFuture
